Zacks Research Has Negative Outlook for TEVA Q3 Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Equities researchers at Zacks Research reduced their Q3 2026 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research note issued on Monday, December 8th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.69 per share for the quarter, down from their prior estimate of $0.71. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2027 earnings at $0.70 EPS and FY2027 earnings at $2.88 EPS.

A number of other equities analysts have also issued reports on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Scotiabank began coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday. Finally, Barclays started coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday. They issued an “overweight” rating and a $35.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $30.25.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $29.74 on Wednesday. The business has a fifty day moving average of $23.03 and a 200-day moving average of $19.44. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $29.80. The firm has a market cap of $34.10 billion, a PE ratio of 49.56, a price-to-earnings-growth ratio of 1.53 and a beta of 0.67.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director directly owned 495,000 shares in the company, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently modified their holdings of the stock. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries in the second quarter valued at approximately $41,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $43,000. Cromwell Holdings LLC increased its holdings in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares during the last quarter. Sound Income Strategies LLC raised its position in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after acquiring an additional 2,824 shares in the last quarter. Finally, MAI Capital Management raised its position in Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after acquiring an additional 697 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.